[{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Johannes Gutenberg University Mainz | Life Sciences Research Partners | Canadian Institutes of Health Research | Instituto de Salud Carlos III | International Network of VENous Thromboembolism Clinical Research Networks | Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Johannes Gutenberg University Mainz | Life Sciences Research Partners | Canadian Institutes of Health Research | Instituto de Salud Carlos III | International Network of VENous Thromboembolism Clinical Research Networks | Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Johannes Gutenberg University Mainz | Life Sciences Research Partners | Canadian Institutes of Health Research | Instituto de Salud Carlos III | International Network of VENous Thromboembolism Clinical Research Networks | Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Ji Xunming","sponsor":"Beijing Friendship Hospital | Beijing Shijitan Hospital, Capital Medical University | Beijing Tongren Hospital | People\u2019s Hospital of Beijing Daxing District | Tianjin Huanhu Hospital | Guizhou Provincial People's Hospital | Shandong Provincial Hospital |","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ji Xunming","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ji Xunming \/ Beijing Friendship Hospital | Beijing Shijitan Hospital, Capital Medical University | Beijing Tongren Hospital | People\u2019s Hospital of Beijing Daxing District | Tianjin Huanhu Hospital | Guizhou Provincial People's Hospital | Shandong Provincial Hospital |","highestDevelopmentStatusID":"10","companyTruncated":"Ji Xunming \/ Beijing Friendship Hospital | Beijing Shijitan Hospital, Capital Medical University | Beijing Tongren Hospital | People\u2019s Hospital of Beijing Daxing District | Tianjin Huanhu Hospital | Guizhou Provincial People's Hospital | Shandong Provincial Hospital |"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Denver Health and Hospital Authority","sponsor":"Genentech | University of Colorado, Denver | National Jewish Health | Beth Israel Deaconess Medical Center | Long Island Jewish Medical Center | Scripps Health | St. Mary's Medical Center | University of Miami | Ben Taub Hospital | The Methodist Hospital ","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Denver Health and Hospital Authority","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Denver Health and Hospital Authority \/ Genentech | University of Colorado, Denver | National Jewish Health | Beth Israel Deaconess Medical Center | Long Island Jewish Medical Center | Scripps Health | St. Mary's Medical Center | University of Miami | Ben Taub Hospital | The Methodist Hospital ","highestDevelopmentStatusID":"8","companyTruncated":"Denver Health and Hospital Authority \/ Genentech | University of Colorado, Denver | National Jewish Health | Beth Israel Deaconess Medical Center | Long Island Jewish Medical Center | Scripps Health | St. Mary's Medical Center | University of Miami | Ben Taub Hospital | The Methodist Hospital "},{"orgOrder":0,"company":"University of Colorado Denver","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of Colorado Denver","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Colorado Denver \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"University of Colorado Denver \/ Inapplicable"},{"orgOrder":0,"company":"Memorial Healthcare System","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Memorial Healthcare System","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Healthcare System \/ Genentech","highestDevelopmentStatusID":"11","companyTruncated":"Memorial Healthcare System \/ Genentech"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Alteplase","moa":"Plasminogen; Fibrinogen alpha chain; Fibrinogen gamma chain; Plasminogen activator inhibitor 1","graph1":"Neurology","graph2":"Phase IV","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Hamilton Health Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"South West Sydney Local Health District","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"South West Sydney Local Health District","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"South West Sydney Local Health District \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"South West Sydney Local Health District \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Undisclosed","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Generium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"RUSSIA","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Generium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Generium \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Alteplase

Alteplase
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check COS database
Check USDMF database

Contact Us
PharmaScopic.com

Alteplase

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

4 API Suppliers, 4 NDC API

DEVELOPMENTS

35 Drugs in Development

35 Drugs in Development

FINISHED DOSAGE FORMULATIONS

24 FDF Dossiers, 3 FDA Orange Book, 17 Europe, 3 Canada, 1 South Africa

DIGITAL CONTENT

4 News #PharmaBuzz

4 News #PharmaBuzz

GLOBAL SALES INFORMATION

11 Annual Reports

11 Annual Reports

MARKET PLACE

4 APIs, 3 FDF Dossiers

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Generium

Russia

Vitafoods

Not Confirmed

02

Ji Xunming

Country

Vitafoods

Not Confirmed

03

South West Sydney Local Health District

Country

Vitafoods

Not Confirmed

04

Hamilton Health Sciences

Canada

Vitafoods

Not Confirmed

05

Boehringer Ingelheim GmbH

Germany

Vitafoods

Not Confirmed

06

Memorial Healthcare System

Country

Vitafoods

Not Confirmed

07

Boehringer Ingelheim GmbH

Germany

Vitafoods

Not Confirmed

08

Assistance Publique – Hôpitaux de Paris

Country

Vitafoods

Not Confirmed

09

Boehringer Ingelheim GmbH

Germany

Vitafoods

Not Confirmed

10

University of Colorado Denver

Country

Vitafoods

Not Confirmed